Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a hold rating to a buy rating in a research report report published on Tuesday morning. They currently have $2.25 target price on the stock.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, ValuEngine cut shares of Ekso Bionics from a buy rating to a hold rating in a research note on Tuesday, October 2nd.
Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Wednesday, November 7th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The company had revenue of $2.55 million for the quarter, compared to the consensus estimate of $2.86 million. Ekso Bionics had a negative return on equity of 257.70% and a negative net margin of 303.58%. As a group, sell-side analysts predict that Ekso Bionics will post -0.45 earnings per share for the current year.
Institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC grew its stake in shares of Ekso Bionics by 136.9% in the third quarter. Citadel Advisors LLC now owns 45,027 shares of the company’s stock worth $105,000 after purchasing an additional 26,017 shares during the last quarter. Bristol Advisors LLC bought a new stake in shares of Ekso Bionics in the third quarter worth $107,000. EAM Investors LLC bought a new stake in shares of Ekso Bionics in the third quarter worth $687,000. Finally, Vanguard Group Inc. grew its stake in shares of Ekso Bionics by 6.3% in the third quarter. Vanguard Group Inc. now owns 1,745,819 shares of the company’s stock worth $4,085,000 after purchasing an additional 103,277 shares during the last quarter. 38.40% of the stock is currently owned by institutional investors.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Featured Story: What is an SEC Filing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.